Background. Invasive aspergillosis (IA) is a major cause of death after hematopoietic stem cell transplantation (HSCT). The goal of this retrospective and consecutive survey was to assess prognostic factors of death due to IA after HSCT at the time of diagnosis of IA.
Invasive aspergillosis (IA) is a major cause of death after stem cell transplantation (HSCT) [1] [2] [3] [4] [5] [6] [7] . Its incidence varies from 5%-8% after receipt of a transplant from an HLA-identical donor, to 10%-25% after receipt of a transplant from an unrelated donor, and to 0.5%-2% after receipt of an autologous transplant. Betweenstudy comparability was poor for a number of reasons, including the lack of a consensus on the definition of the infection, until the European Organization for Research and Treatment of Cancer (EORTC) and the Mycosis Study Group (MSG) published standard definitions on an international level [8] .
Despite these variations in incidence, there is consensus about the poor prognosis of IA in HSCT recipients. The 1-year survival rate after onset of IA in allogeneic HSCT recipients is ∼20% [3] , and such patients always have the highest case-fatality rate among patients with Aspergillus infection [9, 10] .
Although risk factors for IA have been investigated in previous studies [1, 3, 11] , only 1 study has considered prognostic factors for death due to IA after HSCT [12] . Factors identified thus far relate to fungal load, the intrinsic severity of the infection (e.g., cerebral localization), and the extent of patient immunosuppres- sion (e.g., receipt of steroids) [12] . However, the number of patients in this study was limited, and better knowledge about such factors based on findings from a larger number of patients would improve the therapeutic management of IA. The objective of this study was to identify prognostic factors for death due to IA after HSCT using information obtained from the medical records of patients with proven or probable IA in France in 2002.
PATIENTS AND METHODS
All 64 health care centers in the Société Française de Greffe de Moelle et de Thérapie Cellulaire were contacted for participation in this retrospective survey. Of these health care centers, 2 exclusively perform allogeneic HSCT, 29 perform both autologous and allogeneic HSCT, and 33 exclusively perform autologous HSCT. The health care centers were asked to provide data on consecutive IA cases occurring after HSCT for the period of 1 January through 31 December 2002, regardless of the date of transplantation. Informed consent was obtained from living patients or their legal representatives. Definitions. The EORTC-MSG consensus definitions of IA were used to classify the disease [8] . Only proven and probable cases of IA were studied. IA was considered to be disseminated if at least 2 noncontiguous involved sites were identified within 7 days of each other. Steroid treatment was considered to be prolonged if steroids were administered for у2 weeks in the 2 months before IA diagnosis. Aspergillus antigenemia was routinely determined using an ELISA test (Platelia; BioRad) at all of the health care centers. The result of a single test was considered to be positive when the galactomannan index (sample optical density/control optical density [i.e., 1 ng/mL]) was 1 1.
Data collection. Pertinent data concerning the first 4 months after diagnosis of IA or until death (if death occurred earlier) were collected on site from the clinical charts, including the patient's clinical characteristics, imaging reports, microbiological and galactomannan antigenemia data, antifungal drugs used, and outcome. Investigators were required to assess the primary cause(s) of death (e.g., aspergillosis, graft-versus-host disease [GvHD] , and relapse). It was recommended that, in the presence of stable or improving aspergillosis, aspergillosis was not to be considered among the primary causes of death.
Statistical analysis. Descriptive and inferential statistical analyses were performed to compare patients who had died of IA within 4 months after the diagnosis with patients who were still alive at that time. Qualitative variables were compared using the x 2 test or Fisher's exact test, and quantitative variables were compared using a rank sum test. All identified prognostic factors ( ) were further analyzed using a Kaplan-Meier sur-P ! .1 vival model and a Cox model. Selective Cox multiple regression models were also applied to the prognostic factors. All tests were performed bilaterally at the 5% significance level.
RESULTS
After on-site review of the medical charts of the 86 patients reported by the health care centers, data from 51 (41 patients who underwent allogeneic HSCT, and 10 who underwent autologous HSCT) were retained on the basis of the EORTC-MSG criteria. Findings for 35 patients were rejected because of a lack of data to document IA retrospectively. Five cases of IA were proven, and 46 cases of IA were probable. At 4 months after IA diagnosis, 17 patients (37.8%; 95% CI, 23.8%-53.5%) were still alive, and 28 (62.2%; 95% CI, 46.5%-76.2%) had died of causes related to IA. Five patients died of causes unrelated to IA (leukemia relapses in 4 patients and GvHD with multivisceral failure in 1 patient). One patient was lost to follow-up after 103 days. The latter patients were right-censored for survival analyses and were excluded from other inferential analyses.
Patient characteristics. Characteristics of the 51 patients are shown in table 1. The mean age (‫ע‬SD) was 40.1 ‫ע‬ 17.1 years (range, 5-68 years). Six patients had a history of IA before transplantation, and none of the patients received secondary anti-Aspergillus prophylaxis. GvHD was considered by the investigator to be controlled at the time of IA diagnosis in 18 (69.2%) of 26 patients. Nineteen patients (37.3%) were neutropenic (neutrophil count, !500 cells/mm 3 ) at the time of diagnosis of IA, 12 of whom died of IA and 2 of whom died of other causes within 4 months after diagnosis of IA. Thirteen patients (25.5%) had hematological relapse at the time of IA diagnosis, which was 0.3-72 months after transplantation (median time, 5.7 months); 9 patients had relapse after allogeneic HSCT, and 4 patients had relapse after autologous HSCT. Three of these 13 patients were alive 4 months after IA diagnosis, 9 died of causes related to IA, and 1 died of other causes. Eight of these patients were neutropenic as a result of chemotherapy.
The median time that elapsed between transplantation and IA diagnosis was 257 days after autologous HSCT (range, 13-2209 days) and 133 days after allogeneic HSCT (range, 5-980 days). For most patients (42 [82.4%] of 51), the infection was localized to a single organ (lung, sinus, or trachea for 39 patients, 2 patients, and 1 patient, respectively). For 31 patients (60.8%), abnormal findings were detected by chest-radiography, and for 38 patients (74.5%), abnormal findings were detected by thoracic CT. A halo sign was reported at diagnosis for 3 of 38 patients, and no air-crescent sign was reported. Bilateral lung lesions were the most frequent finding (23 of 32 patients for which data were available). Seven patients received a diagnosis of disseminated IA.
For 31 patients (60.8%), a positive galactomannan test result was available within 15 days before or after IA diagnosis, with a first mean index (‫ע‬SD) of . Aspergillus species 3.04 ‫ע‬ 1.79 were detected (by direct examination or culture) in the 12 of 20 sputum samples, 9 of 28 bronchoaspiration samples, and 10 of 28 bronchoalveolar lavage samples. Cultures were positive for Aspergillus fumigatus alone for 21 patients, A. fumigatus plus Aspergillus terreus for 1 patient, and Aspergillus flavus for 1 patient, and the Aspergillus species was not identified for 1 patient.
Information pertaining to fungal prophylaxis was available for 26 (51.0%) of 51 patients. Fluconazole was the most commonly used prophylaxis (14 patients), followed by conventional (3 patients) or liposomal amphotericin B (6 patients) and itraconazole (3 patients).
The drugs that were most frequently prescribed as first-line therapy for IA, alone or in combination, were liposomal amphotericin B (as monotherapy for 13 patients, and in a 2-drug regimen for 6 patients, including 1 who received an investigational drug) and voriconazole (as monotherapy for 10 patients, and in a 2-drug regimen for 4 patients, including 1 patient who received liposomal amphotericin B). Seven patients received other forms of polyenes. Four received itraconazole, and 4 received caspofungin. One patient received itraconazole and caspofungin, and 1 received an investigational drug. In total, 10 patients received a combination of 2 antifungals as first-line treatment, and 2 patients received an investigational treatment. Only 2 patients did not receive any antifungal for IA: one died within 2 days after IA diagnosis, and the second was an allogeneic HSCT recipient had a community-acquired pneumonia 11 year after transplantation. Examination of a bronchoalveolar lavage fluid specimen revealed bacterial pneumonia, which was treated as such and which was quickly cured without any antifungal therapy, although the bronchoalveolar lavage fluid specimen yielded A. fumigatus.
Outcome after occurrence of IA. Four months after IA diagnosis, 1 patient was lost to follow-up with a favorable lastknown status at 103 days after IA diagnosis. The outcome was favorable for 17 (34%) of the remaining 50 patients, and the other 33 patients (66%) died. Aspergillosis was the only cause of death for 2 patients and was among the main causes of death for 26 patients. Five patients died of causes other than IA, including hematological relapse, GvHD, multiple-organ failure, and septic shock.
Four months after the diagnosis of IA, the probability of survival of the whole population ( ) was 0.349. Excluding n p 51 the 6 patients who either died of other causes ( ) or were n p 5 lost to follow-up ( ), the probability of survival was 0.434) n p 1 Risk factors for death due to IA. More than 50 possible covariates were studied. Univariate analyses suggested that neither the underlying disease, the type of transplant (autologous transplant, allogeneic transplant from an HLA-identical donor, or allogeneic transplant from an unrelated donor), the origin of the graft (marrow vs. peripheral stem cells), the number of CD34 + cells infused, nor the cytomegalovirus serologic test findings influenced the outcome of IA. Furthermore, the risk of death was not strongly related to the conditioning regimen for allogeneic transplantation: 6 (66.6%) of 9 patients who underwent nonmyeloablative HSCT and 21 (65.6%) of 32 patients who received a conventional regimen died (of any cause) within 4 months after IA diagnosis.
Patients were divided into 4 age groups (0-11, 12-35, 36-47, and у48 years) to separate very young patients from young adults. Categorical analyses performed on the 4 age groups suggested a strong association between age group and death due to IA ( ). In particular, the data suggested a higher P p .011 risk of death due to IA among teenagers and young adults (figure 2).
Neither fibrinogen level, serum creatinine level, nor neutrophil count at diagnosis (!500 vs. у500 cells/mm 3 ) influenced outcome of IA. The only biological parameter to have influenced the outcome was the monocyte count at diagnosis. A monocyte count of !120 cells/mm 3 (the median value for the cohort) was a pejorative factor ( for IA-related P p .0046 death); 16 of 22 patients with such findings died of IA within 4 months after diagnosis (figure 3).
Disseminated IA was a pejorative prognostic factor (P p ); all 7 affected patients died of IA within 4 months. Pleural .034 effusion, which was present in 10 patients, was strongly related to death due to IA (8 of 10 affected patients died of IA, and 1 patient died of another cause;
for death due to P p .0497 IA). Sixteen (61.5%) of 26 patients who had GvHD at the time of IA diagnosis died of IA, including all 8 patients for whom GvHD was uncontrolled. The influence of uncontrolled GvHD on the outcome of IA was of borderline statistical significance ( ). Three of the 6 patients with a previous history of P p .057 IA before transplantation died of IA-related causes.
IA-related death within 4 months after IA diagnosis was more common among patients who received steroid treatment for 12 weeks within 2 months before IA diagnosis than among patients who did not (74.1% vs. 44.4%;
). Among P p .045 these patients, the frequency of IA-related death was highest for patients who received steroid treatment at a dose of у2 mg/kg at the time of IA diagnosis (14 [87.5%] of 16 patients). A comparison of the 3 strata (no steroid treatment for 12 weeks within 2 months of IA diagnosis, a dose of !2 mg/kg at diagnosis, and a dose of у2 mg/kg at diagnosis) suggested a difference in the distribution of IA-related deaths ( ) P p .030 ( figure 4) .
Seven of the 41 allogeneic HSCT recipients received a cumulative steroid dose of 114 mg/kg within the 2 weeks preceding the diagnosis of IA and had active, acute GvHD (maximum grade, у2) or extensive chronic GvHD. Six of these patients died of IA within 1 month after IA diagnosis, and 1 was still alive after 4 months. On the other hand, the dose of steroid given within the 2 weeks after the diagnosis had no influence on the prognosis. We performed univariate survival analyses of the possible prognostic factors that were identified ( ). Results of the P ! .1 Cox proportional hazards models are presented in table 2. Kaplan-Meier analyses supported these results, and survival curves are shown in figures 1-4. These survival analyses showed strong relationships to the risk of death due to IA ( ) for all P ! .05 parameters studied except sex. The risk of death was especially high for patients with a monocyte count of !120 cells/mm 3 , uncontrolled GvHD, pleural effusion, and receipt of steroid treatment for 12 weeks within 2 months of IA diagnosis and at a dose of у2 mg/kg at the time of diagnosis. NOTE. Possible prognostic factors were identified through use of the usual tests and yielded a P value of !.1. GvHD, graft-versus-host disease.
a Among recipients of allogeneic transplants.
Multivariate Cox models with forward selection (entry level, ) were also applied to the possible prognostic factors. P p .2 For each combination of factors, results suggested that patients aged 12-35 years were 3.2-5.2 (95% CI, 1.2-8.2 to 1.4-18.8) times more likely to die of IA than any other age group analyzed. The results also supported the univariate analyses for the high-risk factors pleural effusion (risk, 3.0; 95% CI, 1.1-8.4), monocyte count of !120 cells/mm 3 (risk, 3.3; 95% CI, 1.4-8.0), and receipt of steroid treatment at a dose of у2 mg/kg at diagnosis (risk, 2.8; 95% CI, 1.3-6.0). The factors uncontrolled GvHD and disseminated IA were only represented by a small number of patients each and were not statistically significant in the multivariate analyses.
The colinearity of the variables included in the multivariate analyses was investigated. There was significant correlation between disseminated IA and steroid treatment ( , by P p .004 Pearson test) and between GvHD and steroid treatment ( , by Pearson test). Exclusion of each of these variables P p .005 from the model one at a time led to a slight increase in the strength of relationship between the remaining variables and death due to IA. In particular, the risk for the variable uncontrolled GvHD increased to 3.4 (95% CI, 1.3-8.8) when the steroid variables were removed from the model.
DISCUSSION
This retrospective consecutive survey aimed to identify potential risk factors for death in 51 consecutive HSCT recipients who received a diagnosis of an episode of proven or probable IA in 2002. This was an exploratory study to describe the strength of the relationship between the factors identified and death due to IA as a reference for future studies.
The analysis of the data pertaining to epidemiological, clinical, and therapeutic features of IA suggested that the risk of death due to IA was especially high among patients with a monocyte count of !120 cells/mm 3 , pleural effusion, uncontrolled GvHD after allogeneic transplantation, and prolonged steroid intake at a dose у2 mg/kg at the time of diagnosis (the risk of IA-related death increased by 2.8, 3.4, 4.0, and 3.1, respectively).
A notable finding that emerged from this study is that, regardless of whether the investigator considered death to be due to or not due to IA, the overall outcomes after IA diagnosis were comparable ( figure 1 ). This suggests that, although IA may be cured or controlled, its occurrence has a poor prognostic significance [3, 7] , likely because of the presence of multiple comorbidities, GvHD, and other infections.
Disseminated IA, including brain involvement, has been associated with a very poor prognosis in many studies [9, 12] , as in ours. Although concomitant pleural effusion cannot be strictly considered to be a sign of dissemination if no Aspergillus species are identified in pleural fluid samples, its presence was associated with an increased risk of death.
Although the neutrophil count did not influence the prognosis in our series, a monocyte count of !120 cells/mm 3 at diagnosis was a strongly pejorative factor. This finding is in agreement with the role of a nonspecific immunity in fungal defense. Also, considering that the dendritic cell population is partially reflected in the circulating monocyte counts, this monocyte defect could also indirectly inform a specific dendritic cell population defect, favoring the poor outcome of IA. Steroid therapy, which is strongly linked to GvHD in allogeneic HSCT, was already identified in a previous series as a major risk factor of poor outcome in IA. Ribaud et al. [12] showed that, among 27 patients, those who received a cumulative prednisone dose 17 mg/kg within the week preceding IA and who had active, acute GvHD of grade у2 or extensive chronic GvHD had the worst prognosis, with 0 of 9 patients surviving. Comparable findings emerged from our study. This should encourage health care providers involved in transplantation to reduce the steroid dose as much as possible.
The analyses suggested that teenagers and young adults (age, 12-35 years) had the highest risk of death due to IA, compared with patients from other age groups. Surprisingly, the older patients in our study (i.e., those aged 147 years) had the best outcomes, with 11 (64.7%) of 17 patients surviving after IA. This does not seem to be linked to the use of different conditioning regimens (i.e., conventional vs. nonmyeloablative treatment). Age is a risk factor for acquiring IA after allogeneic HSCT [1, 3, 4] , although no previous series have studied the impact of age on the prognosis of IA after HSCT. One hypothesis to explain the better survival rate among the older patients could be that the natural immunity to Aspergillus species needs several decades to be acquired. However, the result may just be a chance finding.
Some expected risk factors for death due to IA (e.g., neutropenia was shown to influence the risk of death in a large review [9] ) were not found to be significant in our series. In our study, only one-third of the patients were neutropenic (neutrophil count, !500 cells/mm 3 ) at diagnosis, suggesting that the prognosis of IA could be more influenced by specific immune recovery than by neutrophil counts in the recipients of HSCT.
One cannot determine whether the choice of antifungals has influenced the prognosis of IA from our study. Too many various regimens were used for the groups to be compared. The heterogeneity of treatments may be explained by the fact that voriconazole was only commercially available in France in the mid-2002 [13] . The number of patients was, however, too small to allow any statistical comparison. A larger study is needed to explore the influence of different first-line therapies on the prognosis of IA. Such a study would also allow the role of nontherapeutic factors to be more fully explored within different treatment regimens.
In conclusion, our study identifies important prognostic factors of a demographic, epidemiologic, clinical, and therapeutic nature, auguring perspectives for a better adaptation of the treatment of such high-risk patients. These risk factors should be confirmed by larger series. They could help to build scores of predictivity, which could allow one to identify at bed-side the patients with a higher risk. The prospective trials evaluating more-aggressive therapeutic interventions (i.e., combinations or high doses in first-line treatment regimens) should be reserved in priority for these patients.
